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Background: CUL4A has been proposed as oncogene in several types of human cancer, but its clinical significance
and functional role in human non-small cell lung cancer (NSCLC) remain unclear.
Methods: Expression level of CUL4A was examined by RT-PCR and Western blot. Forced expression of CUL4A was
mediated by retroviruses, and CUL4A silencing by shRNAs expressing lentiviruses. Growth capacity of lung cancer
cells was measured by MTT in vitro and tumorigenesis in vivo, respectively.
Results: We found that CUL4A was highly expressed in human lung cancer tissues and lung cancer cell lines, and
this elevated expression positively correlated with disease progression and prognosis. Overexpression of CUL4A in
human lung cancer cell lines increased cell proliferation, inhibited apoptosis, and subsequently conferred resistance
to chemotherapy. On other hand, silencing CUL4A expression in NSCLC cells reduced proliferation, promoted
apoptosis and resulted in tumor growth inhibition in cancer xenograft model. Mechanistically, we revealed CUL4A
regulated EGFR transcriptional expression and activation, and subsequently activated AKT. Targeted inhibition of
EGFR activity blocked these CUL4A induced oncogenic activities.
Conclusions: Our results highlight the significance of CUL4A in NSCLC and suggest that CUL4A could be a
promising therapy target and a potential biomarker for prognosis and EGFR target therapy in NSCLC patients.
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Lung cancer remains by far the most common cause of
cancer mortality and non-small cell lung cancer (NSCLC)
accounts for >80% of cases of lung cancer, which ranks
among the most deadly cancers worldwide [1]. Although
three therapeutic modalities (surgical resection, chemother-
apy, and radiotherapy) have been established, long-term
survival for lung cancer patients is still generally poor [1,2].
Therefore, further characterization of NSCLC pathogenesis
to identify useful biomarkers and explore novel therapeutic
targets becomes an essential task.* Correspondence: gwwei@yahoo.com
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unless otherwise stated.Epidermal growth factor receptor (EGFR) is a trans-
membrane protein with intrinsic tyrosine kinase activity
that regulates cell growth in response to binding of its li-
gands. EGFR is overexpressed or mutated in most NSCLC
cases, and deregulated expression of EGFR together with
ligand binding and concomitant receptor activation pro-
motes tumor cell growth, proliferation, and survival [3,4].
Several studies have demonstrated that EGFR overexpres-
sion correlates with reduced disease-free and overall
survival [5,6]. Therefore, many strategies including using
specific tyrosine kinase inhibitors (TKI) and monoclonal
antibodies to target EGFR have been developed for treat-
ment of NSCLC [7,8].
CUL4A, a member of the cullin family of proteins that
composes the multifunctional ubiquitin ligase E3 complex,
plays critical roles in DNA replication, cell cycle regulation
and genomic instability [9-15]. CUL4A amplification ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cers, including breast cancer, squamous cell carcinoma,
adrenocortical carcinoma, childhood medulloblastoma,
prostate cancer and hepatocellular carcinoma and is as-
sociated with poor prognosis in node-negative breast can-
cer [16-23]. Recently, it has benn shown that CUL4A is
overexpressed and amplified in 64% primary malignant
pleural mesothelioma, and downregulation of CUL4A
with shRNA causes cell cycle arrest and growth inhibition
through upregulation of p21 and p27 proteins [20]. The
use of a Cul4A transgenic mouse model demonstrates the
potential oncogenic role of Cul4A in lung tumor develop-
ment. After 40 weeks of Cul4A overexpression, lung tu-
mors were visible and were characterized as grade I or II
adenocarcinomas [24]. Kim et al. reported that DLC1 was
ubiquitinated and degraded by cullin 4A-RING ubiquitin
ligase (CRL4A) complex interaction with DDB1 and the
FBXW5 substrate receptor in NSCLC cell lines [25]. The
recently report also shown that EGFR protects proliferat-
ing cell nuclear antigen from cullin 4A protein-mediated
proteolysis [26]. However, the functions and mechanism
of CUL4A in NSCLC development and progression re-
main largely unknown.
In the present work, we sought to investigate the role
and mechanism of CUL4A in NSCLC. We first exam-
ined both mRNA and protein expression patterns and
evaluated prognostic significance of CUL4A in NSCLC.
High levels of CUL4A predicted poor prognosis in over-
all survivals. Moreover, ectopic expression of CUL4A
promoted cell proliferation and inhibited apoptosis.
Knockdown of endogenous CUL4A by shRNA signifi-
cantly decreased cell proliferation and tumorigenesis.
Those oncogenic functions of CUL4A are at least par-
tially mediated by regulation of EGFR and its related
pathways. Additionally, we showed that CUL4A overex-
pression conferred NSCLC cells resistance to chemo-
therapy and sensitivity to EGFR target therapy. Our
findings implicate CUL4A as a promising molecular tar-
get for therapy and a prognostic marker for highly recur-
rent NSCLC.
Results
CUL4A expression is high and associated with prognosis
in lung cancer
We first examined CUL4A expression in a panel of 7
human lung cancer cell lines and 2 normal human lung
epithelial cell lines. RT-PCR (Additional file 1: Figure
S1A) and Western blot (Additional file 1: Figure S1B)
showed high level of CUL4A in nearly all of tumor cell
lines compared with normal human lung epithelial cells.
We then determined CUL4A expression in clinical sam-
ples using RT-PCR. Of 22 NSCLC patients, 18 (81.8%)
had higher CUL4A mRNA levels than adjacent normal
lung tissues (Figure 1A and B). Overall, the averageCUL4A mRNA levels in the cancer tissues were sig-
nificantly higher than that in the normal lung tissues
(P <0.001, Figure 1C). Moreover, we performed immuno-
histochemistry analysis in 78 NSCLC specimens and 56
normal lung tissues and found that CUL4A level was
higher in 87.2% of tumor samples (68 of 78) than that in
normal lung tissue. The CUL4A protein appeared to be
expressed in both cytoplasmic and nuclear components of
tumor cells with stronger signal observed in cytoplasm
(Figure 1D). While the normal bronchial epithelia exhib-
ited undetectable or low CUL4A staining (Figure 1E).
To evaluate the prognostic value of CUL4A expression
in NSCLC, we divided the NSCLC patients into CUL4A
high and low expression groups based on a cutoff score
of 73. Survival analysis revealed that NSCLC patients
with high CUL4A expression had poorer overall survival
than those with low CUL4A expression (P <0.01; Figure 1F).
Next, we analyzed the relationship between CUL4A ex-
pression levels and clinicopathological characteristics.
CUL4A expression was not correlated with gender, age
or tumor subtype (Table 1) but statistically significantly
correlated with NSCLC clinical stages (Table 1). All to-
gether, we demonstrated that CUL4A is overexpressed
in NSCLC and high level of CUL4A expression is a
prognostic predictor of progression and poor clinical
outcome in NSCLC patients.CUL4A regulates NSCLC cell growth and tumorigenesis
In order to test the oncogenic activity of CUL4A in
NSCLC, H1299 and H1650 cells were used to establish
CUL4A overexpressing cell lines and A549 and H460
cells were used to establish CUL4A silencing cell lines
by viral transduction. The levels of CUL4A in these result-
ant cell lines with forced CUL4A expression (designated as
H1299-CUL4A and H1650-CUL4A) and silenced CUL4A
expression (designated as A549-shCUL4A and H460-
shCUL4A) were verified by RT-PCR (Figure 2A) and
Western blot (Figure 2B).
We then used these cell lines to assess the effect of
CUL4A on cell growth by MTT assay. Both H1299-
CUL4A and H1650-CUL4A cell lines had a significant in-
crease in cell proliferation compared with their respective
controls, in contrast, A549-shCUL4A and H460-shCUL4A
cell lines had lower rates of cell proliferation (Figure 2C
and D, Additional file 2: Figure S2A and S2B). To test
whether CUL4A overexpression regulates lung cancer cells
transformation, we examined anchorage-independent cell
growth by soft agar colony formation assay. Numbers of
colonies formed by H1299-CUL4A were significantly
higher than those by pBabe control cells (Additional file 3:
Figure S3A), while the numbers of colonies formed by
A549-shCUL4A were significantly lower than those by
pSuper control cells (Additional file 3: Figure S3B).
Figure 1 (See legend on next page.)
Wang et al. Molecular Cancer 2014, 13:252 Page 3 of 13
http://www.molecular-cancer.com/content/13/1/252
(See figure on previous page.)
Figure 1 CUL4A is overexpressed and associated with prognosis in lung cancer. (A) RT-PCR analysis of CUL4A mRNA in normal lung tissues
(n =22). (B) RT-PCR analysis of CUL4A mRNA in lung cancer tissues (n =22). (C) Relative mRNA levels of CUL4A (normalized to GAPDH) in normal
lung tissues and lung cancer tissues were shown as scatter diagram. (D) Immunohistochemistry analysis of CUL4A protein levels in normal lung
tissues and NSCLC specimens of different subtypes. (E) CUL4A expression scores in normal lung tissues and lung cancer tissues. (F) Survival curves
of NSCLC patients with low versus high expression of CUL4A (n =78; P <0.01, log-rank test). Scale bar indicates 50 μm (D). **P <0.001 vs normal
lung tissues based on Student’s t-test. Experiments in A-B were repeated three times. Error bar indicate standard deviation.
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CUL4A in control of NSCLC cell growth, we analyzed the
apoptotic activity of CUL4A in NSCLC cells. Annexin V
binding assay showed that ectopic CUL4A expression re-
duced the cell proportion in apoptosis and silencing
CUL4A expression drastically increased the population of
apoptotic cells (Figure 2E and F).
To extend our in vitro observations, we investigated
whether CUL4A could regulate tumorigenic capacity of
NCSLC cells in vivo. A549-shCUL4A and its corre-
sponding control cells were subcutaneously injected into
nude mice. Tumor size was measured every other day
up to 40 days. As expected, the tumors from A549-
shCUL4A cells grew less rapidly at the implantation site
than its control cells. After 40 days, tumors were col-
lected and the shCUL4A tumors had a smaller size com-
pared to the pSuper (shCUL4A tumors load to be ~40%
of the size of the pSuper tumors) (Figure 2G and H).
Consistent with these observations, the expression of
major proliferation related protein, Ki67, was modulated
upon CUL4A expression, silencing CUL4A dramatically
decreased the expression levels of Ki67 (Additional file
4: Figure S4). Taking together, these results suggest that
CUL4A is an important regulator of proliferation in lung
cancer cells in vivo.Table 1 Correlation between the clinical pathologic
features and expressions of CUL4A
Characteristics CUL4A P-valuea
Low or None High
Gender Male 21 29 0.732
Female 13 15













bComparing clinical stages I versus II-IV.We then analyzed if CUL4A affect the sensitivity of
NSCLC cells to chemotherapy, H1299 and H1650 cells
with overexpression or A549 and H460 cells with silence
of CUL4A were treated with various doses of docetaxel
and doxorubicin. H1299-CUL4A and H1650-CUL4A
cells displayed significantly higher survival rates than the
vector control cells after treatment for 48 h, whereas the
number of dead cells markedly increased when CUL4A
expression was silenced by specific shRNA (Additional
file 5: Figure S5A-H). These results indicate that CUL4A
overexpression confers docetaxel and doxorubicin resist-
ance in lung cancer cells.
CUL4A regulates EGFR transcriptional expression
As EGFR is overexpressed in NSCLC cells and plays a
key role in the control of cell growth [27], to elucidate
the mechanism by which CUL4A regulates cell growth
in NSCLC, we investigated the effect of CUL4A on
EGFR expression. CUL4A overexpression significantly
increased the level of EGFR transcript, while suppression
of CUL4A dramatically decreased the level of EGFR
transcript (Figure 3A). EGFR protein expression was also
increased by CUL4A overexpression and decreased by
CUL4A silence as evidenced by Western blot and IF
(Figure 3B and C). Given the fact that EGFR expression
is also correlated with poor prognosis in NSCLC [28],
we examined the correlation between EGFR and CUL4A
expression in tumors from patients with NSCLC. As
expected, EGFR expression was found to be positively
correlated with CUL4A level in lung cancer tissues
(Figure 3D). Moreover, we verify the correlation be-
tween EGFR and CUL4A expression by analyzing tumors
generated in nude mice (Additional file 6: Figure S6).
These results indicate that CUL4A regulates the ex-
pression of EGFR.
Our previous study showed that CUL4A regulates his-
tone methylation at H3K4 [29]. Thus, we proposed that
CUL4A may transcriptionally activate EGFR expression
through enrichment of H3K4 trimethylation (H3K4me3)
at EGFR promoter. H1299 and A549 cells were used
to verify our hypothesis. H1299-CUL4A cells showed
higher level and A549-shCUL4A cells had lower level of
H3K4me3 compared with their control cells (Figure 4A).
ChIP assay was then performed using antibody against
H3K4me3 and primers specific to EGFR promoter as
Figure 2 CUL4A regulates NSCLC cell growth both in vitro and in vivo. Ectopic and silencing CUL4A expression in H1299, H1650, A549 and
H460 cells were established by viral transduction. The levels of CUL4A in these resultant cell lines were verified by RT-PCR (A) and Western blot
(B). Cell proliferation in vitro was examined by MTT (C and D). Apoptosis was estimated using Annexin V staining as described in Methods (E and F).
Tumorigenic capacity of A549 and A549-shCUL4A cells was assess in vivo (G, H, and I, n =6). *P <0.05 and **P <0.01 vs pBabe cells; #P <0.05
and ##P <0.01 vs pSuper cells. All results in A to F are from three independent experiments. Error bar indicate standard deviation.
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occupation of H3K4me3 at the EGFR promoter is sig-
nificantly higher in H1299-CUL4A cells compared with
H1299 cells with its control vector (Figure 4C). In
contrast, silencing CUL4A gene expression in A549significantly decrease the H3K4me3 occupation at the
EGFR promoter compared with control cells (Figure 4D).
These data collectively indicated that EGFR is tran-
scriptionally activated by CUL4A expression through
H3K4me3 modulation.
Figure 3 CUL4A regulates EGFR expression. (A) RT-PCR analysis of the expression of EGFR mRNA in H1299, H1650, A549 and H460 cells.
(B) Western blot analysis of the expression of EGFR protein in H1299, H1650, A549 and H460 cells. (C) Immunofluorescence microscopy analysis
of EGFR expression of in H1299, H1650, A549 and H460 cells. (D) The immunohistochemistry analysis of CUL4A and EGFR expression in NSCLC biopsy
showed that CUL4A levels significantly correlate with EGFR levels in NSCLC tissues. All results are from three independent experiments. Scale
bar indicates 20 μm (C), and 50 μm (D).
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Figure 4 CUL4A transcriptionally activates EGFR expression in NSCLC tissues. (A) Western blot analysis of H3K4me3 levels in H1299-pBabe,
H1299-CUL4A, A549-pSuper, and A549-shCUL4A cells. (B) Schematic presentation of two regions relative to the EGFR transcriptional start site used
as primers to test H3K4me3 occupied abundance. (C) ChIP-PCR was performed to assess H3K4me3 occupancy in EGFR promoter in H1299-pBabe
and H1299-CUL4A cells. (D) ChIP-PCR was performed to assess H3K4me3 occupancy in EGFR promoter in A549-pSuper and A549-shCUL4A cells.
IgG was used as negative control.
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Western blot showed that EGFR phosphorylation level
altered in proportion to the change of total EGFR pro-
tein level when CUL4A expression is manipulated in
H1299, H1650, A549 and H460 cells (Figure 5A and B),
which indicates CUL4A may regulate the activation of
EGFR signaling pathways in addition to total EGFR
level. Thus, the phosphorylation and activation of EGFR
downstream target proteins were analyzed. Western
blot results showed that AKT phosphorylation was sig-
nificantly increased by the overexpression of CUL4A al-
though the total level of both AKT was not changed
(Figure 5A), In contrast, silencing CUL4A led to inhib-
ition of phosphorylation of AKT (Figure 5B).
To verify whether the activation of AKT by CUL4A in
NSCLC cells is mediated through EGFR activation,
H1299-CUL4A and its control cells were treated with er-
lotinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKI),
for 4 h. When EGFR phosphorylation was blocked by
erlotinib, CUL4A induced AKT phosphorylation was
reduced (Figure 5C).
To determine if the proliferative effect of CUL4A on
NSCLC cells was EGFR dependent, we treated H1299-
CUL4A, H1650-CUL4A and their control cells with er-
lotinib. Erlotinib clearly reduced the promotive effect of
CUL4A on cell proliferation (Figure 5D). To evaluate
whether CUL4A-EGFR-induced cell proliferation is due
to upregulation of AKT signaling, we compared cell
proliferation rates in H1299-CUL4A and its control
cells in the presence and absence of inhibitor (LY294002)
targeting PI3K. Treatment of the cells with 10 μM
LY294002 blocked the induction of AKT phosphoryl-
ation (Additional file 7: Figure S7A). LY294002 alsoreversed proliferation of H1299 induced by CUL4A
overexpression (Additional file 7: Figure S7B). These re-
sults suggest that Akt signaling activation is essential
for CUL4A-induced proliferation.
Collectively, our data showed that CUL4A promotes
NSCLC cell proliferation through EGFR-AKT pathway
and high level of CUL4A expression sensitizes lung can-
cer cells to erlotinib.
Discussion
To our knowledge, this is the first study to show that
CUL4A has clinical significance and plays a functional
role in human NSCLC. CUL4A was highly expressed in
NSCLC and its expression was correlated with poor
prognosis. Ectopic CUL4A expression in NSCLC cells
induced proliferation and inhibited apoptosis in vitro. In
contrast, silencing CUL4A reversed these events and re-
sulted in inhibition of tumorigenic potential of NSCLC
cells. We also verified a mechanistic link between
CUL4A and EGFR through CUL4A mediated recruit-
ment of H3K4me3 to EGFR promoter, which subse-
quently led to activation of EGFR expression and EGFR
mediated signaling pathways. All of these functions of
CUL4A conferred chemotherapy resistance and EGFR
target therapy sensitivity to NSCLC cells.
Abnormal gene expression plays key roles in tumorigen-
esis which followed by series of target gene alterations and
subsequent biological changes and this cascade of events
is essential to tumorigenesis [30]. In addition to reported
upregulation in breast carcinomas [16,23], high level of
CUL4A expression was also found in squamous cell
carcinoma of the esophagus [31], Adrenocortical carcin-
oma [32], childhood medulloblastoma [33], hepatocellular
Figure 5 CUL4A activates the EGFR-mediated signaling pathways. (A) Levels of CUL4A, EGFR, p-EGFR, p-AKT, and AKT were analyzed by
Western blot in H1299-pBabe, H1299-CUL4A, H1650-pBabe and H1650-CUL4A cells. (B) Levels of CUL4A, EGFR, p-EGFR, p-AKT, and AKT were
analyzed by Western blot in A549-pSuper, A549-shCUL4A, H460-pSuper and H460-shCUL4A cells. (C) Western blot to analyze the effect of erlotinib
on the levels of CUL4A, EGFR, p-EGFR, p-AKT, and AKT in H1299-pBabe and H1299-CUL4A cells. (D) MTT analysis of the inhibition of erlotinib on
cell proliferation in CUL4A overexprssion cells (H1299-CUL4A and H1650-CUL4A). **P <0.01 vs pBabe cells; ##P <0.01 vs pSuper cells. All results are
from three independent experiments. Error bar indicate standard deviation.
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prostate cancer [22]. In this study, we showed that CUL4A
expression is frequently increased in human NSCLC tis-
sues when compared with normal lung tissues and this
elevation was significantly associated with NSCLC pro-
gression and prognosis. CUL4A is proposed as oncogenic
based on its ability to ubiquitinate and degrade tumor
suppressors, such as p21, p27, DDB2 and p53 [11-13,34].
In this report we proposed a novel function of CUL4A in
NSCLC. A serial evidence in our manuscript suggested
that CUL4A activated EGFR transcription and its down-
stream signaling. EGFR signaling network plays a central
role in the growth and maintenance of epithelial tissues,
and alterations of this network can lead to malignanttransformation [35,36]. Overexpression of EGFR was
found in 50-70% of human lung cancer [37], and deregu-
lated expression of EGFR together with ligand binding
and concomitant receptor activation promotes tumor cell
growth, proliferation, and survival [38,39]. Our current
study found that the transactivating activity of EGFR could
be stimulated by CUL4A upregulation and suppressed by
CUL4A inhibition. In addition, CUL4A expression was
found to be positively correlated with overexpression of
EGFR in NSCLC patient tumors. However, the current re-
port just tested the effects of CUL4A on EGFR expression
and did not stratify the situation of EGFR gene amplifica-
tion/ mutation. Such tests with the stratification of EGFR
gene status will greatly expand the relevance of CUL4A to
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mors and will be explored in our future work.
Increased resistance to apoptosis is a hallmark alter-
ation in most types of cancers [1]. Abrogation of proa-
poptotic pathways has been demonstrated to be one of
the events key to tumor development and progression,
and impairments in apoptotic programming are tightly
linked to the commonly seen failure of anticancer chemo-
therapy and radiotherapy [40-42]. Thus, clarification of the
mechanisms modulating the apoptosis/survival process in
a particular cancer type will bring new insights in develop-
ing more effective therapeutic strategies. Notably, in the
current study, we found that CUL4A plays an important
role in antiapoptosis of NSCLC cells that is relatively in-
sensitive to chemotherapy. Ectopic expression of CUL4A
in NSCLC cells dramatically enhances their resistance
to apoptosis induced by doxorubicin or docetaxel, two
commonly used chemotherapeutics, whereas suppress-
ing CUL4A expression with shRNA markedly abrogated
the ability of NSCLC cells to resist cytotoxic reagent-
induced cell death. Our results suggest that CUL4A con-
tributs to sustaining the unwanted survival of NSCLC
cells under the treatment of chemotherapeutics and tar-
geting CUL4A may overcome chemotherapy resistance in
NSCLC with high levels of CUL4A. In summary, our
study demonstrates that NSCLC cells with CUL4A over-
expression are relatively resistant to chemotherapy but
sensitive to EGFR target therapy. Therefore, our experi-
ments provide a good rational to believe that CUL4A is
not only a potential therapeutic target, but also a thera-
peutic biomarker for sensitive to TKI and resistance to
chemotherapy.
Conclusions
In conclusion, we have identified a regulatory network
of CUL4A-induced EGFR expression, which then targets
AKT pathway to modulate cell growth of NSCLC. Our
findings also suggest that CUL4A is not only a potential
therapeutic target but may also serve as a novel prog-
nostic and therapeutic biomarker for NSCLC.
Methods
Patients and specimens
This study was conducted with the approval of the
Shandong University Institutional Ethical Review Board.
Primary tumor specimens were obtained from 78 patients
that underwent complete resection in Qilu Hospital of
Shandong University between 2006 and 2008. Follow-up
information was obtained from review of the patients’
medical record. None of the patients had received radio-
therapy or chemotherapy before surgical resection. All 78
specimens were reevaluated with respect to histological
subtype, differentiation, and tumor stage. The TNM sta-
ging system of the International Union Against Cancerwas used to classify specimens as stages I (n =17), II
(n =20), III (n =25), and IV (n =16). A total of 22 fresh
tumor tissues and 22 fresh normal lung tissues were
stored at −70°C immediately after resection for extrac-
tion of RNA.
Cell lines
BEAS2B, HSAEpiC, A549, H1299, H460, A427, H1650,
95D, and HLAMP cell lines were from American Type
Culture Collection (Manassas, VA). The cells were cultured
in RPMI 1640 (Invitrogen, Carlsbad, CA) containing 10%
fetal calf serum (Invitrogen), 100 IU/ml penicillin (Sigma,
St. Louis, MO), and 100 μg/ml streptomycin (Sigma). Cells
were grown on sterilized culture dishes and were passaged
every 2 days with 0.25% trypsin (Invitrogen).
Establishment of CUL4A stable expressing and
knockdown cell lines
pBabe-puro retroviral constructs containing human CUL4A
cDNA and pSuper.retro.puro with shRNA against human
CUL4A cDNA were prepared as described previously [20].
The constructs were transfected into the HEK 293
Phoenix ampho packaging cells to produce retroviral su-
pernatants. 48 h after transfection, the supernatant was fil-
tered through a 0.25 μm syringe filter. Retroviral infection
was performed by adding filtered supernatant to mam-
mary cell lines in the presence of 8 μg/ml of polybrene
(Sigma, St. Louis, MO, USA). 6 h after infection, medium
was changed with fresh medium and infected cells were
allowed to recover for 48 h. Infected cells were selected by
adding 2 μg/ml puromycin (Sigma, St. Louis, MO, USA)
to the culture medium for 48 h and then maintained
in complete medium with 1 μg/ml puromycin. Empty
retroviral-infected stable cell lines were also produced by
the above protocols. The expression of CUL4A was con-
firmed by RT-PCR and Western blot analysis.
Immunohistochemistry
Immunostaining was performed using the avidin-biotin-
peroxidase complex method (UltrasensitiveTM, MaiXin,
Fuzhou, China). The sections were deparaffinized in xy-
lene, rehydrated with graded alcohol, and then boiled in
0.01 M citrate buffer (pH 6.0) for 2 min with an auto-
clave. Hydrogen peroxide (0.3%) was applied to block
endogenous peroxide activity, and the sections were in-
cubated with normal goat serum to reduce nonspecific
binding. Tissue sections were incubated with CUL4A
rabbit polyclonal antibody (1:250 dilution), EGFR mouse
monoclonal antibody (1:150 dilution). Mouse immuno-
globulin (at the same concentration of the antigen spe-
cific antibody) was used as a negative control. Staining
for both antibodies was performed at room temperature
for 2 h. Biotinylated goat antimouse serum IgG was used
as a secondary antibody. After washing, the sections
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horseradish peroxidase, and the peroxidase reaction was
developed with 3, 30-diaminobenzidine tetrahydrochloride.
Two independent, blinded investigators examined all
tumor slides randomly. Five views were examined per
slide, and 100 cells were observed per view at 400× mag-
nification. Scores for CUL4A and EGFR membrane and
cytoplasmic staining were calculated based on staining
intensity (0, below the level of detection; 1, weak; 2,
moderate; and 3, strong) and the percentage of cells
staining at each intensity level (0-100%). The final score
was calculated by multiplying the intensity score by the
percentage, producing a scoring range of 0 to 300. The
immunohistochemistry score cut-off point was estab-
lished as 73 using X-tile software program (version 3.6.3,
Yale University School of Medicine, CT USA).
RNA Extraction and semi-quantitative RT-PCR
Total cellular RNA was extracted from cells using the
RNeasy Plus Mini Kit from (Qiagen). The quality and
yield of the RNA samples were determined by ultraviolet
spectrophotometer. Total RNAs (1 μg) were reverse
transcribed to cDNA (20 μl) using PrimeScriptTM RT
Kit (TaKaRa) according to the manufacturer’s instruc-
tions. PCR reaction was conducted with 2 μL cDNA
sample, 0.4 μL forward primer (10 μmol/L), 0.4 μL re-
verse primer (10 μmol/L), 11.2 μL RNase-free water, and
6 μL 2× EsayTaq PCR SuperMix (TransGen BIotech,
Beijing, China). PCR reaction was performed using the
following cycle parameters: 95°C for 5 minutes, (94°C
for 30 seconds, 56°C for 30 seconds, 72°C for 45 sec-
onds) for 30 cycles, 72°C for 7 minutes. RT-PCR prod-
ucts were separated on 2% agarose gels. After stained
with ethidium bromide, gel images were photographed
with ChemiImagerTM 4400. RT-PCR was performed at
least 3 times for each sample. The sequences of the
primer pairs are:
CUL4A forward, 5′ ATACTTCAGGACCCACGTTTGAT 3′,
CUL4A reverse, 5′ TCTCCAAGTACTAAAGCAGGA
AAATCT 3′,
EGFR forward, 5′ GCCACGTCTCCACACATCAG 3′,
EGFR reverse, 5′ TGGTGCATTTTCGGTTGTTG 3′,
GAPDH forward, 5′ ATAGCACAGCCTGGATAGCA
ACGTAC- 3′,
GAPDH reverse, 5′ CACCTTCTACAATGAGCT GC
GTGTG 3′.
GAPDH was used as the reference gene.
Western blot analysis
Total protein from cells was extracted in lysis buffer
(Pierce) and quantified using the Bradford method. Then,
50 μg of protein were separated by SDS-PAGE (10%). After
transferring to polyvinylidene fluoride (PVDF) membrane(Millipore, Billerica, MA), the membranes were incubated
overnight at 4°C with antibodies against CUL4A (1:1000;
CST), EGFR (1:1000; Abcam), β-actin (1:2000, Santa Cruz
Biotechnology). After incubation with peroxidase-coupled
antimouse IgG (Santa Cruz Biotechnology) at 37°C for 2 h,
bound proteins were visualized using ECL (Pierce) and de-
tected using BioImaging Systems (UVP Inc., Upland, CA).
The relative protein levels were calculated based on beta-
actin protein as a loading control.
Soft agar assay
The test cells (3 × 105) were suspended in 5ml of culture
medium containing 0.4% agar (USB Corportion) and
seeded onto a base layer of 5ml of 0.7% agar bed in 10-cm
tissure-culture dishes. Colonies >50 μm in diameter were
counted after 3 weeks.
Confocal immunofluorescence microscopy
Cell lines were plated on culture slides (Costar, Manassas,
VA, USA). After 24 hrs, the cells were rinsed with phos-
phatebuffered saline (PBS) and fixed with 4% paraformal-
dehyde in PBS, and cell membrane was permeabilized
using 0.5% Triton X-100. These cells were then blocked
for 30 min in 10% BSA (Sigma, Aldrich St. Louis, MO,
USA) in PBS and then incubated with primary monoclo-
nal antibodies in 10% BSA overnight at 4°C. After three
washes in PBS, the slides were incubated for 1 hour in
the dark with FITC-conjugated secondary goat anti-
mouse, or goat anti-rabbit antibodies (Invitrogen, Grand
Island, NY, USA). After three further washes, the slides
were stained with 4-,6-diamidino-2-phenylindole (DAPI;
Sigma, Aldrich St. Louis, MO, USA) for 5 min to visualize
the nuclei, and examined using an Carl Zeiss confocal im-
aging system (LSM 780) ( Carl Zeiss, Jena, Germany).
MTT assay
Cells were plated in 96-well plates in medium containing
10% FBS at about 3,000 cells per well 24 h after transfec-
tion. Then, 20 μl of 5 mg/ml MTT (Thiazolyl Blue) solu-
tion was added to each well and incubated for 4 h at 37°C,
the media was removed from each well, and the resultant
MTT formazan was solubilized in 150 μl of DMSO. The
results were quantitated spectrophotometrically using a
test wavelength of 570 nm.
Apoptosis assay
Cells were harvested and washed twice with cold PBS by
gentle shaking. Resuspend cells were added to Binding
buffer and adjusted cell density to 2–5 × 105/mL. In the
dark, 5 μL Annexin V-FITC (50 mM TRIS, 100 mM
NaCl, 1% BSA, 0.02% Sodium Azide, pH 7.4) was added
to cell suspension Mix of 195 μL and incubated for 10
min at room temperature before adding 190 μL Binding
buffer (1×) and 10μL PI. Ten thousand events per
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(Becton-Dickinson, San Jose, CA, USA) and the percent-
age of cell apoptosis were analyzed using Cell Quest ana-
lysis software (Becton-Dickinson).
Chromatin immunoprecipitation assays
Cells were fixed in 1% formaldehyde for 10 minutes at 37°C.
Cross-linking was quenched by adding 125 mmol/L
glycine. Cells were then washed with cold PBS, har-
vested and resuspended in SDS lysis buffer containing
a protease inhibitor cocktail. Chromatin was sheared
by sonication (average length 0.25-1 Kb) and incubated
with 60 ml protein A/G agarose/salmon sperm DNA
(50% slurry; Millipore) with gentle agitation for 30 mi-
nutes. The supernatant was then immunoprecipitated
with anti-SOX4 antibody 1:500 or its matched nonim-
mune crude serum 1:500 (IgG; Diagenode) at 4°C over-
night. Protein A/G agarose (60 mL of 50% slurry) was
then added and incubated for 1 hour. Pellets were
washed and protein-DNA cross-links were reversed by
overnight incubation at 65°C with proteinase K. DNA
was purified following a conventional phenol–chloroform
protocol and eluted in 50 mL water. At least 3 independ-
ent Chromatin immunoprecipitation (ChIP) experiments
were carried out.
Xenografted tumor model in vivo
Female BALB/c nude mice (4–5 weeks of age, 18–20 g)
were purchased from the Center of Experimental Animal
of Guangzhou University of Chinese Medicine and were
housed in barrier facilities on a 12-hour light/dark cycle.
All experimental procedures were approved by the Insti-
tutional Animal Care and Use Committee of Shandong
University. The BALB/c nude mice were randomly di-
vided into 2 groups (n =6/group). One group of mice
were inoculated subcutaneously with A549/vector cells
(1 × 106, suspended in 100 μL sterile PBS) per mouse in
the right oxter as control group. The other group was
inoculated with A549/CUL4A shRNA cells (1 × 106, sus-
pended in 100 μL sterile PBS). Tumor volume was cal-
culated using the equation (L ×W2)/2.
Statistical analysis
SPSS version 11.5 for Windows was used for all analyses.
The χ2 test was used to examine possible correlations
between CUL4A expression and clinicopathologic fac-
tors. The association between CUL4A and EGFR immu-
nointensity on the same specimens was analyzed using
Spearman rank correlation test. The t test was used to
compare data from the densitometry analysis of foci
numbers. The Kaplan–Meier method was used to esti-
mate the probability of patient survival, and differences
in the survival of subgroups of patients were compared
using Mantel’s log-rank test. A multivariate analysis wasperformed using the Cox regression model to study the
effects of different variables on survival. P value of <0.05
was considered to indicate statistical significance.
Additional files
Additional file 1: Figure S1. CUL4A is overexpressed in lung cancer
cell lines. (A) RT-PCR analysis of CUL4A mRNA levels in nine lung cell lines.
(B) Western blot analysis of CUL4A protein levels in lung cancer cell lines.
All experiments were repeated three times. Error bar indicate standard
deviation.
Additional file 2: Figure S2. CUL4A regulates NSCLC cell growth both
in vitro. Cell proliferation in vitro was examined by MTT in H1650-pbabe,
H1650-CUL4A (A) and H460-pSuper, H460-shCUL4A (B) cells.
Additional file 3: Figure S3. CUL4A-induced lung cancer cell
transformation in vitro. (A) Photomicrographs illustrating examples of soft
agar colonies (left) and histobars indicating the statistical significance of
the numbers of colonies (right) in H1299-pBabe and H1299-CUL4A cells.
(B) Photomicrographs illustrating examples of soft agar colonies (left) and
histobars indicating the statistical significance of the numbers of colonies
(right) in A549-pSuper and A549-shCUL4A cells. **P <0.01.
Additional file 4: Figure S4. The immunohistochemistry analysis of
Ki67 expression in CUL4A-pBabe and CUL4A-shCUL4A cells xenograft
tumors. Scale bar indicates 50 μm.
Additional file 5: Figure S5. CUL4A regulated the sensitivity of NSCLC
cells to chemotherapy. (A) MTT analysis of the viability of H1299 cell
treated with different doses of doctaxel. (B) MTT analysis of the viability
of H1299 cell treated with different doses of doxorubicin. (C) MTT analysis
of the viability of H1650 cell treated with different doses of doctaxel.
(D) MTT analysis of the viability of H1650 cell treated with different doses
of doxorubicin. (E) MTT analysis of the viability of A549 cell treated with
different doses of doctaxel. (F) MTT analysis of the viability of A549 cell
treated with different doses of doxorubicin. (G) MTT analysis of the
viability of H460 cell treated with different doses of doctaxel. (H) MTT
analysis of the viability of H460 cell treated with different doses of
doxorubicin. *P <0.05 and **P <0.01 vs pBabe cells; #P <0.05 and ##P <0.01
vs pSuper cells. All results are from three independent experiments. Error
bar indicate standard deviation.
Additional file 6: Figure S6. The immunohistochemistry analysis of
CUL4A and EGFR expression in CUL4A-pBabe and CUL4A-shCUL4A cells
xenograft tumors. Scale bar indicates 50 μm.
Additional file 7: Figure S7. LY294002 blocked the CUL4A-induced
AKT phosphorylation and cell proliferation. Treatment of cells with 10 μM
LY294002 blocked the induction of AKT phosphorylation (A). LY294002
also reversed proliferation of H1299 induced by CUL4A overexpression (B).
**P <0.01 vs pBabe cells; ##P <0.01 vs CUL4A cells. All results are from three
independent experiments. Error bar indicate standard deviation.
Abbreviations
CUL4A: Cullin 4A; NSCLC: Non-small cell lung cancer; shRNA: Short hairpin RNA;
FBS: Fetal bovine serum; PVDF: Polyvinylidene difluoride; TBST: Tris-buffered
saline containing tween 20; BSA: Bovine serum albumin; ECL: Enhanced
chemiluminescence; PBS: Phosphate-buffered saline; FACS: Fluorescence-
activated cell sorting; ChIP: Chromatin immunoprecipitation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GWW designed the experiments. WYS, ZPJ, WQ, WMX, and YHT performed
the experiments. LZM, MJH and WYL performed the statistical analysis. WYS
and GWW wrote the manuscript. All authors approved the final draft of this
manuscript.
Acknowledgements
This work was supported by National Natural Science Foundation of China
No. 81172528, 31271461, 81472583, Doctoral Fund of Ministry of Education
Wang et al. Molecular Cancer 2014, 13:252 Page 12 of 13
http://www.molecular-cancer.com/content/13/1/252of China No. 20110131110035, Natural Science Foundation of Shandong
Province No. ZR2011HM034, and the Taishan Scholar Program of Shandong
Province (GW); by the National Institutes of Health, National Cancer Institute
grant R01 CA116481, and the Low Dose Scientific Focus Area, Office of Biological
& Environmental Research, US Department of Energy (DE-AC02-05CH11231)
(JHM); by National Natural Science Foundation of China No.81402193 (WYS); by
National Natural Science Foundation of China No.81470127 (ZPJ).
Author details
1Department of Anatomy and Key Laboratory of Experimental Teratology,
Ministry of Education, Shandong University School of Medicine, 44 Wenhua
Xi Road, Jinan, Shandong 250012, P.R. China. 2Department of International
Biotechnology R&D Center, Shandong University School of Ocean, 180
Wenhua Xi Road, Weihai, Shandong 264209, P.R. China. 3Department of
Biochemistry and Molecular Biology, Shandong University School of
Medicine, 44 Wenhua Xi Road, Jinan, Shandong 250012, P.R. China.
4Department of Neurosurgery, The Fifth People’s Hospital, 447 Jingshen
Road, Jinan 250022, P.R. China. 5Department of Anesthesiology, Qilu Hospital,
Shandong University, 107 Wenhua Xi Road, Jinan 250012, P.R. China.
6Department of Pathology, Shandong Cancer Hospital and Institute, Jinan
250012, P.R. China. 7Life Sciences Division, Lawrence Berkeley National
Laboratory, Berkeley, CA 94127, USA.
Received: 4 June 2014 Accepted: 10 November 2014
Published: 21 November 2014References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin
2012, 62:10–29.
2. Raine R, Wong W, Scholes S, Ashton C, Obichere A, Ambler G: Social
variations in access to hospital care for patients with colorectal, breast,
and lung cancer between 1999 and 2006: retrospective analysis of
hospital episode statistics. BMJ 2010, 340:b5479.
3. Littlefield P, Jura N: EGFR lung cancer mutants get specialized. Proc Natl
Acad Sci U S A 2013, 110:15169–15170.
4. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, Tang C, Ellison G, McCormack R,
Ji Q: The diagnostic accuracy of pleural effusion and plasma samples
versus tumour tissue for detection of EGFR mutation in patients with
advanced non-small cell lung cancer: comparison of methodologies.
J Clin Pathol 2013, 66:1065–1069.
5. Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M,
Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL: Nuclear EGFR
protein expression predicts poor survival in early stage non-small cell
lung cancer. Lung Cancer 2013, 81:138–141.
6. Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, Takeoka
H, Zaizen Y, Kawayama T, Kage M, Hoshino T: Prognostic value of EGFR
mutation and ERCC1 in patients with non-small cell lung cancer
undergoing platinum-based chemotherapy. PLoS One 2013, 8:e71356.
7. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T,
Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanka T, Tajima K,
Harada R, Fukuoka M, Yamamoto N: Erlotinib alone or with bevacizumab
as first-line therapy in patients with advanced non-squamous non-small-
cell lung cancer harbouring EGFR mutations (JO25567): an open-label,
randomised, multicentre, phase 2 study. Lancet Oncol 2014, 15:1236–1244.
8. Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E, Luberto L,
D’Andrilli A, Coluccia P, Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L,
Mancini R, Ciliberto G: Combination therapy with anti-ErbB3 monoclonal
antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Oncotarget 2013, 4:1253–1265.
9. Lee J, Zhou P: Pathogenic Role of the CRL4 Ubiquitin Ligase in Human
Disease. Front Oncol 2012, 2:21.
10. Sugasawa K: The CUL4 enigma: culling DNA repair factors. Mol Cell 2009,
34:403–404.
11. Nag A, Bagchi S, Raychaudhuri P: Cul4A physically associates with MDM2
and participates in the proteolysis of p53. Cancer Res 2004, 64:8152–8155.
12. Li B, Jia N, Kapur R, Chun KT: Cul4A targets p27 for degradation and
regulates proliferation, cell cycle exit, and differentiation during
erythropoiesis. Blood 2006, 107:4291–4299.
13. Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T, Tsurimoto T: CDK
inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupledCul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol
Chem 2008, 283:29045–29052.
14. Han JH, Zhang H, Zhang HL, Wang ZQ, Zhou H, Zhang ZG: A Cul4 E3
Ubiquitin Ligase Regulates Histone Hand-Off during Nucleosome
Assembly. Cell 2013, 155:817–829.
15. Hu J, Xiong Y: An evolutionarily conserved function of proliferating cell
nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase
in response to DNA damage. J Biol Chem 2006, 281:3753–3756.
16. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, Dairkee SH,
Wernick M, Collins C, Smith HS: The human homologue for the
Caenorhabditis elegans cul-4 gene is amplified and overexpressed in
primary breast cancers. Cancer Res 1998, 58:3677–3683.
17. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J: TFDP1,
CUL4A, and CDC16 identified as targets for amplification at 13q34 in
hepatocellular carcinomas. Hepatology 2002, 35:1476–1484.
18. Schindl M, Gnant M, Schoppmann SF, Horvat R, Birner P: Overexpression of
the human homologue for Caenorhabditis elegans cul-4 gene is
associated with poor outcome in node-negative breast cancer. Anticancer
Res 2007, 27:949–952.
19. Liu L, Lee S, Zhang J, Peters SB, Hannah J, Zhang Y, Yin Y, Koff A, Ma L,
Zhou P: CUL4A abrogation augments DNA damage response and
protection against skin carcinogenesis. Mol Cell 2009, 34:451–460.
20. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT,
Jablons DM, You L: Cul4A is an oncogene in malignant pleural
mesothelioma. J Cell Mol Med 2011, 15:350–358.
21. Birner P, Schoppmann A, Schindl M, Dinhof C, Jesch B, Berghoff AS,
Schoppmann SF: Human homologue for Caenorhabditis elegans CUL-4
protein overexpression is associated with malignant potential of
epithelial ovarian tumours and poor outcome in carcinoma. J Clin Pathol
2012, 65:507–511.
22. Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, Lu J, Wei M, Lu X, Gao X, Liang Y,
Mao JH, Sun Y: Oncogenic CUL4A determines the response to
thalidomide treatment in prostate cancer. J Mol Med 2012, 90:1121–1132.
23. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM,
Honrado E, Campoverde A, Palacios J, Nathanson KL, Garcia MJ, Benitez J:
Comprehensive characterization of the DNA amplification at 13q34 in
human breast cancer reveals TFDP1 and CUL4A as likely candidate
target genes. Breast Cancer Res 2009, 11:R86.
24. Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley
D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L: Lung tumourigenesis in a
conditional Cul4A transgenic mouse model. J Pathol 2014, 233:113–123.
25. Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL,
Bang YJ, Der CJ: CRL4A-FBXW5-mediated degradation of DLC1 Rho
GTPase-activating protein tumor suppressor promotes non-small cell
lung cancer cell growth. Proc Natl Acad Sci U S A 2013, 110:16868–16873.
26. Lo YH, Ho PC, Wang SC: Epidermal growth factor receptor protects
proliferating cell nuclear antigen from cullin 4A protein-mediated
proteolysis. J Biol Chem 2012, 287:27148–27157.
27. Charpidou A, Blatza D, Anagnostou V, Syrigos KN: Review. EGFR mutations
in non-small cell lung cancer–clinical implications. In Vivo 2008,
22:529–536.
28. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Ogawa J:
Combined overexpression of EGFR and estrogen receptor alpha
correlates with a poor outcome in lung cancer. Anticancer Res 2005,
25:4693–4698.
29. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen
KY, LaBarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G: CUL4A Induces
Epithelial-Mesenchymal Transition and Promotes Cancer Metastasis by
Regulating ZEB1 Expression. Cancer Res 2014, 74:520–531.
30. Oxnard GR, Binder A, Janne PA: New targetable oncogenes in non-small-
cell lung cancer. J Clin Oncol 2013, 31:1097–1104.
31. Shinomiya T, Mori T, Ariyama Y, Sakabe T, Fukuda Y, Murakami Y, Nakamura
Y, Inazawa J: Comparative genomic hybridization of squamous cell
carcinoma of the esophagus: the possible involvement of the DPI gene
in the 13q34 amplicon. Genes Chromosomes Cancer 1999, 24:337–344.
32. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P:
Adrenocortical carcinoma is characterized by a high frequency of
chromosomal gains and high-level amplifications. Gene Chromosome
Canc 2000, 28:145–152.
33. Michiels EMC, Weiss MM, Hoovers JMN, Baak JPA, Voute PA, Baas F,
Hermsen MAJA: Genetic alterations in childhood medulloblastoma
Wang et al. Molecular Cancer 2014, 13:252 Page 13 of 13
http://www.molecular-cancer.com/content/13/1/252analyzed by comparative genomic hybridization. J Pediat Hematol Onc
2002, 24:205–210.
34. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Praetorius-Ibba M, Wani AA: Cullin
4A-mediated proteolysis of DDB2 protein at DNA damage sites regulates
in vivo lesion recognition by XPC. J Biol Chem 2006, 281:13404–13411.
35. Hagiwara K, Kobayashi K: Importance of the cytological samples for the
epidermal growth factor receptor gene mutation test for non-small cell
lung cancer. Cancer Sci 2013, 104:291–297.
36. Boutayeb S, Bensouda Y, Fadoulkhair Z, Bakkraoui K, Bachouchi M, Errihani H:
[Targeted therapies in digestive oncology]. Pathol Biol (Paris) 2012, 60:264–268.
37. Cagle PT, Allen TC: Lung cancer genotype-based therapy and predictive
biomarkers: present and future. Arch Pathol Lab Med 2012, 136:1482–1491.
38. Rossi A, Pasquale R, Esposito C, Normanno N: Should epidermal growth
factor receptor tyrosine kinase inhibitors be considered ideal drugs for
the treatment of selected advanced non-small cell lung cancer patients?
Cancer Treat Rev 2013, 39:489–497.
39. Laurie SA, Goss GD: Role of epidermal growth factor receptor inhibitors in
epidermal growth factor receptor wild-type non-small-cell lung cancer.
J Clin Oncol 2013, 31:1061–1069.
40. Jendrossek V: The intrinsic apoptosis pathways as a target in anticancer
therapy. Curr Pharm Biotechnol 2012, 13:1426–1438.
41. Mansilla S, Llovera L, Portugal J: Chemotherapeutic targeting of cell death
pathways. Anticancer Agents Med Chem 2012, 12:226–238.
42. Broadhead ML, Dass CR, Choong PF: Cancer cell apoptotic pathways
mediated by PEDF: prospects for therapy. Trends Mol Med 2009,
15:461–467.
doi:10.1186/1476-4598-13-252
Cite this article as: Wang et al.: CUL4A overexpression enhances lung
tumor growth and sensitizes lung cancer cells to Erlotinib via transcriptional
regulation of EGFR. Molecular Cancer 2014 13:252.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
